Esperion puts hope in Rosenberg as new CMO
This article was originally published in Scrip
Executive Summary
Esperion Therapeutics, the US company focused on cardiovascular and metabolic diseases, has appointed Dr Noah Rosenberg as its chief medical officer. He will lead the clinical advisory board and manage the company's clinical programmes, including managing the regulatory review process and corporate planning for financing development programmes. Previously, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi-Aventis and Forest Laboratories.